Risk of cancer by transferrin saturation levels and haemochromatosis genotype: Population-based study and meta-analysis

Journal of Internal Medicine

Volumn 271, Issue 1, 2012, Pages 51-63

  Ellervik, C ^a,b,c   Tybjaerg Hansen A ^c,d,e   Nordestgaard, B G ^a,c,e  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NAESTVED HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Follow up; Haemochromatosis genotype; Meta analysis; Transferrin saturation

Indexed keywords

ADULT; AGED; ANUS CANCER; ARTICLE; BILIARY TRACT CANCER; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER RISK; CANCER SCREENING; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCRINE TUMOR; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GENOTYPE; HAZARD RATIO; HEMOCHROMATOSIS; HODGKIN DISEASE; HUMAN; HYPOTHESIS; IRON OVERLOAD; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MALE; META ANALYSIS; METASTASIS; MOUTH CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; SARCOMA; SKIN CANCER; SMALL INTESTINE CANCER; SMOKING; STOMACH CANCER; TESTIS CANCER; THYROID CANCER; TRANSFERRIN BLOOD LEVEL; URINARY TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

ADULT; AGED; FEMALE; GENOTYPE; HEMOCHROMATOSIS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSFERRIN;

EID: 83855165812     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02404.x     Document Type: Article

References (47)

1. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160: 1-40.
2. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996; 5: 19-36.
3. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
4. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004; 350: 2383-97.
5. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66, 000 cases and 226, 000 controls. Hepatology 2007; 46: 1071-80.
6. Mainous AG III, Wells BJ, Koopman RJ, Everett CJ, Gill JM. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. Am J Epidemiol 2005; 161: 1115-22.
7. Mainous AG III, Gill JM, Everett CJ. Transferrin saturation, dietary iron intake, and risk of cancer. Ann Fam Med 2005; 3: 131-7.
8. Herrinton LJ, Friedman GD, Baer D, Selby JV. Transferrin saturation and risk of cancer. Am J Epidemiol 1995; 142: 692-8.
9. Ioannou GN, Weiss NS, Kowdley KV. Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer. Clin Gastroenterol Hepatol 2007; 5: 624-9.
10. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988; 319: 1047-52.
11. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994; 56: 364-9.
12. Wurzelmann JI, Silver A, Schreinemachers DM, Sandler RS, Everson RB. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 503-7.
13. Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004; 14: 195-201.
14. van IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995; 24: 665-70.
15. Kato I, Dnistrian AM, Schwartz M et al. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer 1999; 80: 693-8.
16. Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T. Body iron stores and risk of cancer. Int J Cancer 1994; 56: 379-82.
17. Cross AJ, Gunter MJ, Wood RJ et al. Iron and colorectal cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study. Int J Cancer 2006; 118: 3147-52.
18. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev 2001; 59: 140-8.
19. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004; 45(Suppl 2): S3-9.
20. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J Clin Oncol 2008; 26: 542-8.
21. Storm HH. The Danish Cancer Registry, a self-reporting national cancer registration system with elements of active data collection. IARC Sci Publ 1991; 220-36.
22. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997; 44: 535-9.
23. Storm HH. Completeness of cancer registration in Denmark 1943-1966 and efficacy of record linkage procedures. Int J Epidemiol 1988; 17: 44-9.
24. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
25. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358: 1405-9.
26. Harrison-Findik DD. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 2007; 13: 4925-30.
27. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of Genetic Epidemiology. New York, NY: Oxford University Press, 1993.
28. Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care. BMJ Books, 2003.
29. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11: 193-206.
30. Broedbaek K, Poulsen HE, Weimann A et al. Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med 2009; 47: 1230-3.
31. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol 2009; 4: 489-515.
32. Harrison-Findik DD, Schafer D, Klein E et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 2006; 281: 22974-82.
33. Beutler E, Bothwell TH, Charlton RW, Motulsky AG. Hereditary hemochromatosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill, 2001; 3127-62.
34. McNaughton SA, Mishra GD, Paul AA, Prynne CJ, Wadsworth ME. Supplement use is associated with health status and health-related behaviors in the 1946 British birth cohort. J Nutr 2005; 135: 1782-9.
35. Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J Hepatol 2010; 2: 302-10.
36. Tas F, Hansel H, Belce A et al. Oxidative stress in breast cancer. Med Oncol 2005; 22: 11-5.
37. Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007; 60: 1-7.
38. Olsson KS, Ritter B, Raha-Chowdhury R. HLA-A3-B14 and the origin of the haemochromatosis C282Y mutation: founder effects and recombination events during 12 generations in a Scandinavian family with major iron overload. Eur J Haematol 2010; 84: 145-53.
39. Milet J, Dehais V, Bourgain C et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet 2007; 81: 799-807.
40. Zacharski LR, Chow BK, Howes PS et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100: 996-1002.
41. Edgren G, Reilly M, Hjalgrim H et al. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 2008; 100: 572-9.
42. Geier D, Hebert B, Potti A. Risk of primary non-hepatocellular malignancies in hereditary hemochromatosis. Anticancer Res 2002; 22: 3797-9.
43. Brissot P, Moirand R, Guyader D, Loreal O, Turlin B, Deugnier Y. Hemochromatosis after the gene discovery: revisiting the diagnostic strategy. J Hepatol 1998; 28(Suppl 1): 14-8.
44. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-9.
45. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010; 56: 1570-9.
46. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-19.
47. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008; 149: 270-2.